Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Handel & varor |
| Industri | Dagligvaror |
2023-02-15 07:00:00
15 February 2023: Aker BioMarine ASA ("Aker BioMarine" or "the company") reports
revenues of USD 79 million and Adjusted EBITDA of USD 21 million for the fourth
quarter 2022.
Highlights fourth quarter:
- Revenues of USD 79 million in Q4 2022, up 4% from same quarter last year
- Adjusted EBITDA of USD 21 million in Q4 2022, up from USD 7 million the same
quarter last year
- In the quarter, the company initiated an improvement program to streamline
operations, improve margins and cut cost. The implementation of such measures
started early 2023
- Offshore production volume was 1,960 MT in the quarter and total volume for
the full year was 52,000 MT, 19% higher than in 2021
"Aker BioMarine delivered 6% revenue growth in 2022 with an adjusted EBITDA
margin of 25%, up from 18% in 2021. In the year, we improved our krill
harvesting and progressed both our ingredients and Brands business. To further
strengthen our core business and create a more robust company, we have initiated
an improvement program, where our goal is to realize annualized effects in
excess of USD 20 million within the next two years", said Matts Johansen, CEO of
Aker BioMarine.
At 09:00 CET today, the management hosts a webcast. Following the presentation,
there will be a Q&A session, where written questions can be submitted to
ir@akerbiomarine.com.
The webcasted presentation will be in English. To join, please use the link that
is available at www.akerbiomarine.com/investor.
A replay of the presentation and Q&A session material will be made available
soon after the presentation at the same web address.
For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.